Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lung Neoplasms 20Ovarian Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Fallopian Tube Neoplasms 13Colorectal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Hepatocellular 9Melanoma 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Breast Neoplasms 6Urinary Bladder Neoplasms 5Prostatic Neoplasms 5Neoplasm Metastasis 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Carcinoma, Renal Cell 5Neoplasms 4Uterine Cervical Neoplasms 3Sezary Syndrome 3Sarcoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Endometrial Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3

Interventions

Rituximab 259Cyclophosphamide 238Etoposide 114Prednisone 97Vincristine 96Doxorubicin 96Peripheral Blood Stem Cell Transplantation 95fludarabine phosphate 87Filgrastim 80Cytarabine 61Lenalidomide 60Mycophenolic Acid 59Melphalan 59Radiotherapy 58Busulfan 52Cyclosporine 50Carmustine 49Whole-Body Irradiation 48Tacrolimus 46Methotrexate 42Antilymphocyte Serum 38Gemcitabine 33Ifosfamide 32Carboplatin 32fludarabine 31Dexamethasone 31polatuzumab vedotin 29Granulocyte Colony-Stimulating Factor 29CT-P10 28Methylprednisolone 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Large B-Cell, Diffuse × Immunoglobulin G × Clear all
NCT04007029 2025-09-05

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
24 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02706405 2022-08-24

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Terminated
30 enrolled 29 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡